Navigation Links
Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
Date:10/23/2008

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) today announced that an abstract entitled "Phase I Trial of Oncolytic Reovirus (REOLYSIN(R)) in Combination with Carboplatin/Paclitaxel in Patients with Advanced Solid Cancers" will be available in the November/December issue of the Journal of Immunotherapy, the official journal of the International Society for Biological Therapy of Cancer (iSBTc). The principal investigator for the trial is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

The abstract covers results of the trial (REO 011) up to July 2008. At that time, 11 patients had received 46 cycles of treatment, with no dose-limiting toxicities. Of the 10 evaluable patients, there were three patients with a partial response, five patients with stable disease and two patients with progressive disease. On the basis of promising response data in the patients with head and neck cancers, a Phase II study has been opened in head and neck cancer patients using the 3x10(10) TCID(50) dose on five consecutive days.

A poster presentation that will include current results of the trial is scheduled to be presented on November 1, 2008 at the iSBTc annual meeting. The meeting is being held in San Diego, California from October 31-November 2, 2008.

The poster should be available on the Oncolytics website at http://www.oncolyticsbiotech.com on November 3, 2008.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visi
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... 2015  Sonoa Health, a health tech startup based ... a world-first consumer health portal, Health&, which brings together ... and more. Today, the Company appointed respected ... who brings to the table more than 18-years experience ... working closely with the biggest names in Silicon Valley ...
(Date:3/31/2015)... NEW YORK , March 31, ... ), a biopharmaceutical company advancing protein biologic therapies ... its Korean marketing partner, Hanmi Pharmaceutical Co., Ltd ... Korea from the country,s Ministry of Food and ... Research Institute (KTR) for MuGard, its oncology supportive-care ...
(Date:3/31/2015)... OH (PRWEB) March 31, 2015 Diasome ... its licensor, SDG, Inc., that a United States patent ... liver-targeted insulin therapy. , Entitled “Lipid Construct ... covers composition of matter claims related to the use ... system for enabling injected insulin to more effectively reach ...
(Date:3/30/2015)... -- Multiple new research abstracts suggest walnuts may have the ... their impact on colon cancer and certain aspects of ... health and vascular health, the research findings presented at ... walnuts, inner workings. Running March 28 through April 1 ... attracts an international audience of over 14,000 leading research ...
Breaking Biology Technology:Investment Banker Appointed CEO of Australian Health Tech Start-Up 2Investment Banker Appointed CEO of Australian Health Tech Start-Up 3PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4
... TUCSON, Ariz., Oct. 24, 2011 Ventana Medical Systems, ... 510(k) clearance from the U.S. Food and Drug Administration ... image analysis applications with associated VIRTUOSO software and iScan ... with a complete workflow solution for determining HER2 (4B5) ...
... Syndax Pharmaceuticals, Inc ., a late-stage epigenetics oncology company, announced today ... conferences: BIO Investor Forum , San Francisco, ... Discovery on Target , Panel Discussion: HDACi and Their Progress in ... Lazard Annual Healthcare Conference , New York, NY, November 16, 1:30 ...
... a diagnostic company focused on breath analysis for the ... a Small Business Innovation Research (SBIR) contract by the ... I/II Fast-Track contract will support the research and development ... Metabolomx, proprietary technology is designed to recognize ...
Cached Biology Technology:Ventana Receives FDA Clearance for HER2 (4B5) Image Analysis and Digital Read Applications 2Syndax Pharmaceuticals to Present at Upcoming Fall Conferences 2Metabolomx Awarded $1.14 Million SBIR Grant from National Cancer Institute for Breath Analysis Test of Lung Cancer 2
(Date:3/12/2015)... -- Beta Systems today announced Fast ... (IAM) solution for a fixed price and with ... IAM package, customers benefit from the 30 years, ... implementations across different industries. The new fixed-price IAM ... necessary services and consulting. It spans the implementation ...
(Date:3/10/2015)... 2015  Continuing its 167-year history of offering the ... The Eye Scanning Password Authenticator , a device ... secure websites or sensitive data. Employing the ... borders, the device has a small camera that scans ... iris, converting them into an encrypted ID that cannot ...
(Date:3/5/2015)... 2015 In Brazil , cloud ... using these solutions and 42 percent planning to invest in ... 25 percent of the companies will be investing in these ... of companies in the region are currently opting for the ... will command significant attention in the coming years. This trend ...
Breaking Biology News(10 mins):Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... ARLINGTON, Va. Dr. Linda Chrisey, a leading scientist at ... electricity from bacteria found in mud and wastewater during National ... the process of testing the utility of the microbial fuel ... value to us," said Chrisey, a program officer for ONR,s ...
... YORK (May 6, 2010) The Wildlife Conservation Society ... large, "landscape-wide" conservation approach to protect globally important populations ... at wildlife populations in northern Republic of Congo over ... a community-managed reserve, and various logging concessions. It ...
... German , French , Spanish , Chinese ... sequenced the Neandertal genome, using pill-sized samples of bone powder from ... appear in the 7 May issue of the journal Science ... The researchers, led by Svante Pbo of the Max-Planck Institute for ...
Cached Biology News:ONR scientist generates 'mud power' for NPR radio audience 2Study looks at gorillas, elephants and logging in Congo 2Study looks at gorillas, elephants and logging in Congo 3Neandertal genome sequence published in Science 2Neandertal genome sequence published in Science 3Neandertal genome sequence published in Science 4
... pan B (B220), 4.5 m, coated ... efficient positive isolation or depletion of ... or lymph node cell suspensions. B220 ... cells and lytically active subsets of ...
... (IC50 = 59.2 M). Formula: ... O 13 MolWeight: ... RT CAS: ... to 100 mM in DMSO IUPAC: ...
POU domain, class 2, transcription factor 2,...
NAP-2 (5C7)...
Biology Products: